Aliskiren: beyond blood pressure reduction.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Hypertension is a primary risk factor for cardiovascular disease (CVD).
• Renin-angiotensin-aldosterone system (RAAS) inhibitors, including ACE inhibitors and ARBs, are crucial for blood pressure management and organ function.
• Understanding RAAS pathways is key to managing complex cardiovascular conditions.

Purpose of the Study:

• To review the effectiveness and safety of aliskiren beyond its role in hypertension treatment.
• To explore aliskiren's potential in managing conditions associated with increased cardiovascular risk.
• To evaluate aliskiren's broader therapeutic applications.

Main Methods:

• This is a review article.
• Focuses on existing literature regarding aliskiren's efficacy and safety.
• Analyzes aliskiren's mechanism of action and potential clinical applications.

Main Results:

• Aliskiren is the first approved direct renin inhibitor, blocking angiotensin I generation.
• Its mechanism suggests potential to inhibit atherosclerosis progression at the tissue level.
• Aliskiren may be beneficial in conditions like stable coronary artery disease (CAD), cardio-renal disease, diabetes, and peripheral arterial disease (PAD).

Conclusions:

• Enhanced blockade of the RAAS through therapies like aliskiren can lead to improved outcomes in hypertension-related organ damage.
• Aliskiren presents a potential therapeutic option for a wide range of cardiovascular conditions.
• Further research may elucidate aliskiren's full potential in managing complex diseases.